title: Mucosa-reparing and microbiota-balancing therapeutic effect ofBacillus subtilisalleviates dextrate sulfate sodium-induced ulcerative colitis in mice.
abstract: Gut microbiota composition of patients with ulcerative colitis (UC) is markedly altered compared with healthy individuals. There is mounting evidence that probiotic therapy alleviates disease severity in animal models and patients with inflammatory bowel disease (IBD).Bacillus subtilisis, as a probiotic, has also demonstrated a protective effect in IBD. However, the therapeutic mechanism of its action has yet to be elucidated. In the present study, a dextrose sulfate sodium (DSS)-induced UC mouse model was used to investigate the role ofB. subtilisin the restoration of gut flora and determine its effective dose. Mucosal damage was assessed by performing alcian blue staining, cytokine levels were analyzed by ELISA and microbiota composition was investigated using 454 pyrosequencing to target hypervariable regions V3-V4 of the bacterial 16S ribosomal RNA gene. The results demonstrated that a higher doseB. subtilisisadministration ameliorated DSS-induced dysbiosis and gut inflammation by balancing beneficial and harmful bacteria and associated anti- and pro-inflammatory agents, thereby aiding intestinal mucosa recovery from DSS-induced injuries. These findings indicate that choosing the correct dose ofB. subtilisis important for effective UC therapy. The present study also helped to elucidate the mechanisms ofB. subtilisaction and provided preclinical data forB. subtilisuse in UC therapy.
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Hui-Lu
authors.initials: HL
authors.lastname: Zhang
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Wen-Shuai
authors.initials: WS
authors.lastname: Li
authors.affiliation: Department of Immunology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Dian-Nan
authors.initials: DN
authors.lastname: Xu
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Wan-Wei
authors.initials: WW
authors.lastname: Zheng
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Zhi-Bing
authors.initials: ZB
authors.lastname: Qiu
authors.affiliation: MD Candidate, Class of 2018, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
authors.forename: Robert G
authors.initials: RG
authors.lastname: Dorfman
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China; Department of Immunology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
keywords: Bacillus subtilis; mouse; ulcerative colitis